Evidence map›Paper›PMID 37354221›Full record

ArticleDiscover oncology2023

Human epidermal growth factor 2 overexpressed alpha-fetoprotein-producing-gastric cancer.

Hiroko Shimizu, Mitsugu Kochi, Masashi Fujii, Megumu Watabe, Yoritaka Matsuno, Takaharu Kawai, Hiroshi Suda, Tomoyuki Tanino, Yoko Nakanishi, Shinobu Masuda and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Guideline
  2. Review
  3. [Novel clinical insights and frontier issues in alpha- fetoprotein-producing gastric cancer].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026
    Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Hiroko ShimizuDivision of Digestive Surgery, Department of Surgery, Nihon University School of Medicine, Tokyo, Japan.
Mitsugu KochiDivision of Digestive Surgery, Department of Surgery, Nihon University School of Medicine, Tokyo, Japan.
Masashi FujiiJapan Clinical Cancer Research Organization, Tokyo, Japan.
Megumu WatabeDivision of Digestive Surgery, Department of Surgery, Nihon University School of Medicine, Tokyo, Japan.
Yoritaka MatsunoDivision of Digestive Surgery, Department of Surgery, Nihon University School of Medicine, Tokyo, Japan.
Takaharu KawaiDivision of Digestive Surgery, Department of Surgery, Nihon University School of Medicine, Tokyo, Japan.
Hiroshi SudaDivision of Digestive Surgery, Department of Surgery, Nihon University School of Medicine, Tokyo, Japan.
Tomoyuki TaninoDivision of Oncologic Pathology, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.
Yoko NakanishiDivision of Oncologic Pathology, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan. nakanishi.youko@nihon-u.ac.jp.
Shinobu MasudaDivision of Oncologic Pathology, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.
Yukiyasu OkamuraDivision of Digestive Surgery, Department of Surgery, Nihon University School of Medicine, Tokyo, Japan.
Nihon University · JPJapan Clinical Cancer Research Organization · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to elucidate the clinicopathological characteristics of α-fetoprotein (AFP)-producing gastric carcinoma (AFP-GC) with human epidermal growth factor receptor (HER)2 overexpression to extend the treatment strategy for AFP-GC.

methodsWe analyzed 41 patients with AFP-GC who underwent surgical resection or chemotherapy from 1989 to 2019, and who had over 20ng/mL of serum AFP or positive immunohistochemical AFP expression. HER2 expression status was investigated by immunohistochemistry (IHC) for all patients and by fluorescence in situ hybridization (FISH) for cases with an IHC score of 2+. AFP-GC with an IHC score of 3 + or 2 + and FISH positivity was defined as HER2 overexpressed AFP-GC. The correlation between HER2 status and clinicopathological characteristics and prognosis in AFP-GC was analyzed.

resultsHER2 overexpression was detected in 17.1% of AFP-GC patients. The prognosis of the patients with HER2 overexpressed AFP-GC was not significantly different compared to HER2 non-overexpressed AFP-GC. HER2 overexpressed AFP-GC consisted of heterogeneous histology with a higher proportion of mixed-type tumors (p = 0.002). The clinical outcome of AFP-GC with mixed-type of histology tended to be better than other intestinal or diffuse types (p = 0.05).

conclusionHER2 overexpressed AFP-GC consisted of a mixed type of histology, which showed a better prognosis. The results presented that HER2 status in AFP-GC is one of the molecular candidates to improve the prognosis.

Indexed as

AFP-producing gastric cancerHER2Mixed histological subtype

Identifiers

PMID37354221
PMCPMC10290623
OpenAlexW4381889813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.